

Short Research Article

Radiolabelling of meso-2,3-DMSA with ^{177}Lu . Preliminary results regarding the stability and biospecificity of ^{177}Lu -DMSA[†]

VALERIA LUNGU*, DIANA CHIPER and DANA NICULAE

*Horia Hulubei National Institute for Physics and Nuclear Engineering, Bucharest-Magurele, Romania, 407 Atomistilor, Magurele, judet Ilfov, postal code 077125, P.O. Box MG 6, Bucharest, Romania

Received 27 July 2006; Revised 16 January 2007; Accepted 20 January 2007

Keywords: lutetium-177; DMSA; radiolabelling; stability; biospecificity

Introduction

In this paper we present the radiolabelling methods of meso-2,3-dimercaptosuccinic acid (DMSA) with ^{177}Lu (45 Ci/mg specific activity) from Nordion Canada as therapeutic radionuclide ($T_{1/2} = 6.7$ days, $E_{\beta} = 0.5$ MeV, $E_{\gamma} = 0.208$ MeV). The following kinetics parameters were studied: pH (between 5 and 9 range, in sodium acetate buffer and sodium bicarbonate buffer, respectively) and incubation temperature (room temperature and 100°C). The DMSA quantity (1 mg) used in the radiolabelling process and the incubation time (1 h) were maintained constant in all the kinetic studies.^{1–5}

Results and discussion

The quality control studies by paper and thin layer chromatography show that the radiolabelling gave high yield (>95%) and radiochemical purity (>95%) in sodium bicarbonate buffer and 1 h at 100°C incubation conditions. The stability studies show that radiochemical purity of the ^{177}Lu -DMSA kept 48 h in room temperature conditions is higher than 95%; after this time the radiochemical purity of ^{177}Lu -DMSA decreases below 80% (Table 1). For the evaluation of the biological affinity of ^{177}Lu -DMSA were used the HRS1

tumor bearing rats. The serial scintigrams were obtained at 3 h, 12 h, 24 h, after i.v. injection with 200–300 μCi of ^{177}Lu -DMSA. The images (Figures 1–3) show: fast blood clearance; significant uptake and stability of ^{177}Lu -DMSA in the tumor and low bone accumulation in excellent bone to tumor radioactive ratios. The obtained results are promising and encourage further investigations for estimation of favorable properties of ^{177}Lu -DMSA as a potential agent for targeted radiotherapy of cancer.






Figure 1 Image of HRS1 bearing tumor rat at 3 h after i.v. injection with ^{177}Lu -DMSA. Figure available in colour online at www.interscience.wiley.com

*Correspondence to: Valeria Lungu, 'Horia Hulubei' National Institute for Physics and Nuclear Engineering, Radiopharmaceuticals and Labelled Compounds, 407 Atomistilor, Magurele, Bucharest 077125, Romania. E-mail: vlungu2000@yahoo.com

[†]Proceedings of the Ninth International Symposium on the Synthesis and Applications of Isotopically Labelled Compounds, Edinburgh, 16–20 July 2006.

Table 1 Radiochemical Purity of ^{177}Lu -DMSA

Samples	Solvents	Radiochemical purity (%)
DMSA- ^{177}Lu , pH = 5	0.1 M sodium citrate, pH = 5	62
DMSA- ^{177}Lu , pH = 9	10% ammonium acetate: MeOH = 30:70	57
DMSA- ^{177}Lu , pH = 9	0.1 M sodium citrate, pH = 5	98

**Figure 2** Image of HRS1 bearing tumor rat at 12 h after iv injection with ^{177}Lu -DMSA. Figure available in colour online at www.interscience.wiley.com**Figure 3** Image of HRS1 bearing tumor rat at 24 h after iv injection with ^{177}Lu -DMSA. Figure available in colour online at www.interscience.wiley.com

REFERENCES

1. Kothari K, Satpati D, Mukherjee A, Sarma HD, Venkatesh M, Pillai MRA. *J Label Compd Radiopharmaceut* 2002; **45**: 675–686.
2. Blower PJ, Lam ASK, O'Doherty MJ, Kettle AG, Coakley AJ, Knapp FF. *Eur J Nucl Med* 1998; **25**: 613–621.
3. Hourichi-Suzuki K, Arano Y, Saji H, Yokoyama A. *TECDOC IAEA-SM-355/33*; 44–45.
4. Kothari K, Pillai MRA, Unni PR, Mathakar AR, Shimpi HH, Noronha OPD, Samuel AM. *TECDOC IAEA-SM-355/71*; 1–13.
5. Ramamoorthy N *et al.* *Eur J Nucl Med* 1987; **12**: 623–628.